摘要
目的:探讨慢性阻塞性肺疾病(COPD)患者氧化/抗氧化失衡的发生机制及氨溴索的干预作用,为COPD患者的治疗提供更新有效的方法。方法:1.基础方面:36只Wistar雄性大鼠,随机分成3组(每组n=12):1)正常对照组,2)低氧组,3)氨溴索干预组。后2组大鼠均制成慢性低氧性肺动脉高压模型。常规方法检测肺动脉平均压,比色法检测全血及肺组织SOD及血浆LPO和NO的含量,并进行肺细小动脉形态测定。2.临床方面:将符合要求的42例患者随机分成2组;氨溴索治疗组(A组,n=20),阳性对照组(B组,n=22)。健康老年人20例为正常对照组(C组)。分别于入院后的第2,8,15天抽血比色法检测全血超氧化物歧化酶(SOD)及血浆过氧化脂质(LPO)和一氧化氮(NO)的含量。同步进行血气分析和检测血浆P-选择素的水平,并进行病情评分。结果:1.基础方面:1)氨溴索干预组大鼠血液和肺组织SOD和NO水平明显高于低氧组,而血液和肺组织LPO水平明显降低;2)氨溴索干预组肺细小动脉管壁厚度占外径百分比和管壁面积占总面积百分比明显比低氧组高。2.临床方面:1)A、B两组治疗前的SOD、NO、LPO及血浆P-选择素水平无显著性差异;2)治疗7天后,A组的SOD的水平明显比B组低;3)治疗14天后,A组患者的病情评分显著低于B组。
Objective: To investigate the mechanism of the oxidant/antioxidant imbalance of patients with COPD and the attenuation effect of ambroxol. Methods: 1 .Basic study 36 male Wistar rats were randomly divided into 3 groups(n =12) : 1) normal control;2) chronically intermittent hypoxia(CIH) ;3) ambroxol protect group(AP) .The last 2 groups were made into hypoxic models and the mean pulmonary artery pressure (PAPM) were determined , the level of blood and lung homogenates SOD(Superoxidase Dismu-tase) 、 NO (Nitric oxidate)、 LPO(Lipid Poxidatin) were determined, Each of the right low lung was sent for histolical exama-tion. 2. Clinical study : 42 patients suited for the creatia were randomly divided into 2 groups: Group A (20 patients were draingedwitham-broxol, 60mg/day, bid) ; Group B122 patients didn't use ambroxol) .And 20 healthy old subjects were enrolled as Group C.In the patients of Group A and Group B, the level of blood SOD and plasma NO and LPO were determined on the 2ed ,8th, 15th day after they were in hospital. also determined the level of plasma P - selectin. Blood analysis were done stimultaneously. The score of illness were also calculated at the same time. Results: 1. Basic study 1) The level of blood and lung homogenates SOD and NO in AT were significantly higher than CIH,and the level of plasma and lung homogenates LPO were significantly lower; 2) Relative tube wall thickness and relative tube wall area of pulmonary arteries were obviously increased in CIH as compared with those of normal contral and AP group. 2. Clinic study : 1) no difference were found between group A and group B in the level of blood SOD and plasma NO、LPO and P - selectin before treatment; 2) 7 days later, the level of blood SOD in group A is significantly higher than that of group B, but no difference in the level of plasma NO and LPO; 14days later, the level of blood SOD in group A is significantly higher than that of group B, the level of plasma LPO in group A is significantly lower than that of group B 3) 14 days later, the illness score in group A is significantly lower than that of group B; Conclusion: Ambroxol can attenuate the oxidant/ antioxidant imbalance in CIH rats and COPD patients, the clinic use can benefit to COPD patients.
出处
《中国医药导刊》
2001年第4期260-262,共3页
Chinese Journal of Medicinal Guide
